Pancreatic Cancer Research

ResearcherTranslational Genomics Research InstituteActive in the last 2 years

Gayle Jameson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0987-5965; OpenAlex author ID A5003323232. Sources: ClinicalTrials.gov.

Their work

Papers
19 (first author 2, last author 0)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
0
Collaborators
72
Papers, trials and grants by year

2013: 1 trial · 2014: none · 2015: none · 2016: 1 paper, 1 trial · 2017: 2 papers, 1 trial · 2018: none · 2019: none · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 5 papers · 2026: 5 papers

Papers 19

  1. A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancre… Co-author DOI 10.1002/cncr.70343↗
  2. Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer". Co-author DOI 10.1002/cncr.70510↗
  3. Corrigendum to "Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer" [… Co-author DOI 10.1016/j.redox.2026.104395↗
  4. A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer. First author DOI 10.1093/oncolo/oyag232↗
  5. Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer. First author DOI 10.36401/jipo-25-20↗
  6. Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer. Co-author DOI 10.1016/j.redox.2025.103895↗
  7. Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-025-03167-2↗
  8. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Co-author DOI 10.1093/oncolo/oyae323↗
  9. Retrospective analysis of capecitabine maintenance therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359251321894↗
  10. Skin microbiome differences in pancreatic adenocarcinoma, other cancers, and healthy controls: a pilot study. Co-author DOI 10.3389/fonc.2025.1495500↗
  11. Hand therapy interventions for the prevention of chemotherapy-induced peripheral neuropathy of the hands in patients with pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae285↗
  12. Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-Wo… Co-author DOI 10.1093/oncolo/oyac217↗
  13. Mitomycin C in Homologous Recombination Deficient Metastatic Pancreatic Cancer after Disease Progression on Platinum-Based Chemotherapy and Olaparib. Co-author DOI 10.3390/biomedicines10112705↗
  14. Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase 1b/2 Pilot C… Co-author DOI 10.1001/jamaoncol.2019.3394↗
  15. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Co-author DOI 10.1186/s13073-020-00776-9↗
  16. An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocar… Co-author DOI 10.18632/oncotarget.27586↗
  17. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2017.209↗
  18. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Co-author DOI 10.21037/jgo.2017.09.05↗
  19. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗

Trials 3

  1. Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) Principal investigator NCT03410030↗
  2. Hand Therapy Intervention Versus Traditional Occupational Therapy to Prevent Chemotherapy Induced Peripheral Neuropathy Principal investigator NCT05374876↗
  3. Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA Principal investigator NCT01893801↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Erkut Hasan Borazanci · 15 shared papers, 2020–2026 · strength 3.10
  2. Daniel D. Von Hoff · 15 shared papers, 2017–2026 · strength 2.57
  3. Haiyong Han · 7 shared papers, 2017–2026 · strength 1.26
  4. Derek Cridebring · 5 shared papers, 2020–2026 · strength 0.98
  5. Michael T. Barrett · 6 shared papers, 2017–2026 · strength 0.85
  6. Joshua D. Rabinowitz · 3 shared papers, 2025–2026 · strength 0.71
  7. Ronald M. Evans · 3 shared papers, 2025–2026 · strength 0.63
  8. Alexa F. Viniotis · 2 shared papers, 2025–2026 · strength 0.53
  9. Drew Warren Rasco · 2 shared papers, 2026 · strength 0.51
  10. Diana L. Hanna · 2 shared papers, 2026 · strength 0.51
  11. David J. Propper · 2 shared papers, 2025–2026 · strength 0.44
  12. Angela Tatiana Alistar · 2 shared papers, 2025–2026 · strength 0.42
  13. Ronald Lee Korn · 2 shared papers, 2022–2026 · strength 0.38
  14. Taylor L. Davis · 1 shared paper, 2025 · strength 0.33
  15. Albert Amini · 2 shared papers, 2020–2026 · strength 0.32
  16. Jordan Powell · 1 shared paper, 2025 · strength 0.30
  17. Muhammad Rizwan Khawaja · 1 shared paper, 2026 · strength 0.25
  18. Boris Ν. Kholodenko · 1 shared paper, 2026 · strength 0.25
  19. Syed Rahmanuddin · 1 shared paper, 2026 · strength 0.22
  20. Richard C. Frank · 1 shared paper, 2026 · strength 0.22
  21. Kuntal Halder · 1 shared paper, 2025 · strength 0.21
  22. Mitsuro Kanda · 1 shared paper, 2025 · strength 0.21
  23. Lin Wei · 1 shared paper, 2025 · strength 0.21
  24. Haruyoshi Tanaka · 1 shared paper, 2025 · strength 0.21
  25. Mohammed Aldakkak · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.